For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Sunesis Pharmaceuticals, Inc.

USPTO Granted Patents = 63

CIPO Patents = 10

EPO Patents = 26

Trademarks = 1

Forward Citations = 487

Loading Chart...

Loading Chart...

123 inventors (with patents filed for the assignee):

Daniel A Erlanson (14 out of 17 patents)

Gnanasambandam Kumaravel (11 out of 60 patents)

Anantha R Sudhakar (11 out of 47 patents)

4. Noel Aaron Powell (10 out of 15 patents)

5. Brian T Hopkins (10 out of 32 patents)

6. Patrick R Conlon (10 out of 28 patents)

7. Bing Guan (10 out of 17 patents)

8. Tracy J Jenkins (10 out of 19 patents)

9. Alexey Alexandrovich Lugovskoy (8 out of 50 patents)

10. Min Zhong (8 out of 41 patents)

11. Deping Wang (8 out of 34 patents)

12. Brian Raimundo (8 out of 14 patents)

13. Daniel M Scott (8 out of 27 patents)

14. Jeffrey A Silverman (7 out of 7 patents)

15. Art Taveras (6 out of 6 patents)

Core Competencies:

Bruton's Tyrosine Kinase Inhibitors

Pyrimidinyl Tyrosine Kinase Inhibitors

PDK1 Inhibitors

Raf Kinase Inhibitors

SNS-595

Stable Compositions

Cancer Treatment

Beta-Secretase Inhibitors

Heterocyclic Compounds

Aurora Kinase Inhibitors

Therapeutic Combinations

Enzymatic Activity Modulators

63 patents: Sort by Forward Citations

1. 11174243 - Succinate forms and compositions of Bruton's tyrosine kinase inhibitors (2021-11-16),

2. 10618887 - Pyrimidinyl tyrosine kinase inhibitors (2020-04-14),

3. 10577374 - Bruton's tyrosine kinase inhibitors (2020-03-03),

4. 10107798 - Methods of chemotype evolution (2018-10-23),

5. 10030016 - Heterocyclic compounds useful as PDK1 inhibitors (2018-07-24),

6. 9980949 - SNS-595 and methods of using the same (2018-05-29),

7. 9969730 - Stable SNS-595 compositions and methods of preparation (2018-05-15),

8. 9944622 - Pyrimidinyl tyrosine kinase inhibitors (2018-04-17),

9. 9920048 - Substituted pyrimidines for inhibiting Raf kinase activity (2018-03-20),

10. 9873693 - Methods of treatment using pyridinonyl PDK1 inhibitors (2018-01-23),

11. 9839630 - Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid (2017-12-12),

12. 9790229 - Bruton's tyrosine kinase inhibitors (2017-10-17),

13. 9757363 - SNS-595 and methods of using the same (2017-09-12),

14. 9724338 - Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders (2017-08-08),

15. 9676774 - Compounds and compositions for treatment of cancer (2017-06-13),

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of hematologic and solid cancers. They aim to improve the lives of patients through effective and targeted therapies. With a strong commitment to research and development, Sunesis is dedicated to advancing novel drug candidates and bringing them to market.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

63 Patents

#21 in South San Francisco, CA

#1,314 in California

#5,579 in US

#11,347 in the World

South San Francisco, CA, United States of America

Sunesis Pharmaceuticals, Inc.

Forward Citations = 487

123 inventors:

Daniel A Erlanson (14 out of 17 patents)

Gnanasambandam Kumaravel (11 out of 60 patents)

Anantha R Sudhakar (11 out of 47 patents)

4. Noel Aaron Powell (10 out of 15 patents)

5. Brian T Hopkins (10 out of 32 patents)

Please report any incorrect information to support@idiyas.com

Loading…